Pier Paolo Claudio, M.D., Ph.D. (Marshall University Graduate Faculty, Cancer Biology research cluster), was an invited speaker at the prestigious Cancer Stem Cell Conference at Case Western University in August. Claudio traveled to Cleveland, OH to provide the ChemoID clinical trial data for the Central Nervous System (CNS) tumor series in a presentation titled: Chemosensitivity Assay for Targeting Cancer Stem-Like Cells in Malignant Brain Tumors. His work was well-received by the 500 world-renowned, national, and international cancer scientists who attended the conference. The opportunity to present his results was “extremely rewarding,” said Claudio.
ChemoID is the result of Claudio’s focus on translational research which is aimed at taking laboratory discoveries to a patient’s bedside. He and his collaborators have developed a method of forecasting the efficacy of particular chemotherapy drugs on specific individuals diagnosed with certain types of cancers. This tool for choosing the best personalized therapy for cancers such as brain, lung, or breast, in addition to others, has shown very positive results in the clinical trials leading to hospital use of the technology.
On October 15, the Edwards Comprehensive Cancer Center will implement ChemoID. Additionally, transportation stability studies have shown that national and international samples can be safely sent to Claudio’s lab paving the way for broad use of this method.
Claudio noted that, “among all the talks presented at the meeting, we were one of the few institutions presenting an actual completed clinical trial with promising results. This certainly increased our national exposure and the number of collaborations with other leading institutions in the field.”